Journal of the National Cancer Institute
-
J. Natl. Cancer Inst. · Jan 2015
Comparative StudyCost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing.
Population-based testing for BRCA1/2 mutations detects the high proportion of carriers not identified by cancer family history (FH)-based testing. We compared the cost-effectiveness of population-based BRCA testing with the standard FH-based approach in Ashkenazi Jewish (AJ) women. ⋯ Population-based screening for BRCA mutations is highly cost-effective compared with an FH-based approach in AJ women age 30 years and older.